Brokerages Set Sanofi (NASDAQ:SNY) Price Target at $57.50

Shares of Sanofi (NASDAQ:SNY) have received a consensus rating of “Moderate Buy” from the four brokerages that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $57.50.

A number of research firms have issued reports on SNY. StockNews.com upgraded shares of Sanofi from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 30th. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Argus increased their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $52.85 on Friday. The firm has a market cap of $134.12 billion, a PE ratio of 26.96, a PEG ratio of 1.36 and a beta of 0.61. The firm has a fifty day moving average of $55.85 and a 200 day moving average of $52.10. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a one year low of $45.00 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the prior year, the firm earned $2.55 earnings per share. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, research analysts predict that Sanofi will post 4.27 EPS for the current fiscal year.

Institutional Trading of Sanofi

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northwest Investment Counselors LLC purchased a new stake in Sanofi in the 3rd quarter valued at about $29,000. POM Investment Strategies LLC acquired a new position in shares of Sanofi in the 2nd quarter valued at about $25,000. Concord Wealth Partners lifted its stake in shares of Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares in the last quarter. Larson Financial Group LLC lifted its stake in shares of Sanofi by 480.8% in the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after purchasing an additional 500 shares in the last quarter. Finally, Arrow Financial Corp acquired a new position in shares of Sanofi in the 2nd quarter valued at about $35,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.